The expression and significance of long non-coding RNA ITGB2-AS1 in renal clear cell carcinoma

References

1. 1.↵
   1. Padala SA,
   2. Barsouk A,
   3. Thandra KC,
   4. Saginala K,
   5. Mohammed A,
   6. Vakiti A, et al.

   Epidemiology of renal cell carcinoma. World J Oncol 2020; 11: 79–87.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Chen Y,
   2. He F,
   3. Wang R,
   4. Yao M,
   5. Li Y,
   6. Guo D, et al.

   NCF1/2/4 are prognostic biomarkers related to the immune infiltration of kidney renal clear cell carcinoma. Biomed Res Int 2021; 2021: 5954036.

   OpenUrl
3. 3.↵
   1. Jiang H,
   2. Chen H,
   3. Wan P,
   4. Chen N.

   Decreased expression of HADH is related to poor prognosis and immune infiltration in kidney renal clear cell carcinoma. Genomics 2021; 113: 3556–3564.

   OpenUrl
4. 4.↵
   1. Xu J,
   2. Wu KJ,
   3. Jia QJ,
   4. Ding XF.

   Roles of miRNA and lncRNA in triple-negative breast cancer. J Zhejiang Univ Sci B 2020; 21: 673–689.

   OpenUrl
5. 5.
   1. Ghafouri-Fard S,
   2. Hussen BM,
   3. Gharebaghi A,
   4. Eghtedarian R,
   5. Taheri M.

   LncRNA signature in colorectal cancer. Pathol Res Pract 2021; 222: 153432.

   OpenUrl
6. 6.↵
   1. Huang L,
   2. Xie Y,
   3. Jiang S,
   4. Han W,
   5. Zeng F,
   6. Li D.

   The lncRNA signatures of genome instability to predict survival in patients with renal cancer. J Healthc Eng 2021; 2021: 1090698.

   OpenUrl
7. 7.↵
   1. Dai J,
   2. Xu LJ,
   3. Han GD,
   4. Jiang HT,
   5. Sun HL,
   6. Zhu GT, et al.

   Down-regulation of long non-coding RNA ITGB2-AS1 inhibits osteosarcoma proliferation and metastasis by repressing Wnt/β-catenin signalling and predicts favourable prognosis. Artif Cells Nanomed Biotechnol 2018; 46: S783–S790.

   OpenUrl
8. 8.↵
   1. Liu M,
   2. Gou L,
   3. Xia J,
   4. Wan Q,
   5. Jiang Y,
   6. Sun S, et al.

   LncRNA ITGB2-AS1 could promote the migration and invasion of breast cancer cells through up-regulating ITGB2. Int J Mol Sci 2018; 19: 1866.

   OpenUrl
9. 9.↵
   1. Tsagakis I,
   2. Douka K,
   3. Birds I,
   4. Aspden JL.

   Long non-coding RNAs in development and disease: conservation to mechanisms. J Pathol 2020; 250: 480–495.

   OpenUrlCrossRef
10. 10.↵
    1. Rinn JL,
    2. Chang HY.

    Long noncoding RNAs: molecular modalities to organismal functions. Annu Rev Biochem 2020; 89: 283–308.

    OpenUrlCrossRefPubMed
11. 11.
    1. Yang W,
    2. Zhang K,
    3. Li L,
    4. Ma K,
    5. Hong B,
    6. Gong Y, et al.

    Discovery and validation of the prognostic value of the lncRNAs encoding snoRNAs in patients with clear cell renal cell carcinoma. Aging (Albany NY) 2020; 12: 4424–4444.

    OpenUrl
12. 12.
    1. Cox A,
    2. Tolkach Y,
    3. Kristiansen G,
    4. Ritter M,
    5. Ellinger J.

    The lncRNA Fer1L4 is an adverse prognostic parameter in clear-cell renal-cell carcinoma. Clin Transl Oncol 2020; 22: 1524–1531.

    OpenUrl
13. 13.
    1. Bohosova J,
    2. Kubickova A,
    3. Slaby O.

    lncRNA PVT1 in the pathogenesis and clinical management of renal cell carcinoma. Biomolecules 2021; 11: 664.

    OpenUrl
14. 14.
    1. Hamilton MJ,
    2. Young M,
    3. Jang K,
    4. Sauer S,
    5. Neang VE,
    6. King AT, et al.

    HOTAIRM1 lncRNA is downregulated in clear cell renal cell carcinoma and inhibits the hypoxia pathway. Cancer Lett 2020; 472: 50–58.

    OpenUrl
15. 15.↵
    1. Gong K,
    2. Xie T,
    3. Luo Y,
    4. Guo H,
    5. Chen J,
    6. Tan Z, et al.

    Comprehensive analysis of lncRNA biomarkers in kidney renal clear cell carcinoma by lncRNA-mediated ceRNA network. PLoS One 2021; 16: e0252452.

    OpenUrl
16. 16.↵
    1. Gu J,
    2. He Z,
    3. Huang Y,
    4. Luan T,
    5. Chen Z,
    6. Wang J, et al.

    Clinicopathological and prognostic value of necroptosis-associated lncRNA model in patients with kidney renal clear cell carcinoma. Dis Markers 2022; 2022: 5204831.

    OpenUrl
17. 17.↵
    1. Zhang W,
    2. Lu Y,
    3. Shi H,
    4. Li X,
    5. Zhang Z,
    6. Deng X, et al.

    LncRNA ITGB2-AS1 promotes the progression of clear cell renal cell carcinoma by modulating miR-328-5p/HMGA1 axis. Hum Cell 2021; 34: 1545–1557.

    OpenUrl
18. 18.↵
    1. Zhang L,
    2. Tao H,
    3. Li J,
    4. Zhang E,
    5. Liang H,
    6. Zhang B.

    Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma. Aging (Albany NY) 2021; 13: 15990–16008.

    OpenUrl
19. 19.↵
    1. Braga EA,
    2. Fridman MV,
    3. Moscovtsev AA,
    4. Filippova EA,
    5. Dmitriev AA,
    6. Kushlinskii NE.

    LncRNAs in ovarian cancer progression, metastasis, and main pathways: ceRNA and alternative mechanisms. Int J Mol Sci 2020; 21: 8855.

    OpenUrl
20. 20.↵
    1. Yang X,
    2. Zhang Y,
    3. Fan H.

    Downregulation of SBF2-AS1 functions as a tumor suppressor in clear cell renal cell carcinoma by inhibiting miR-338-3p-targeted ETS1. Cancer Gene Ther 2021; 28: 813–827.

    OpenUrl
21. 21.↵
    1. Qi Q,
    2. Sun Y,
    3. Yang Y,
    4. Liu Y.

    Circ_0000274 contributes to renal cell carcinoma progression by regulating miR-338-3p/NUCB2 axis and JAK1/STAT3 pathway. Transpl Immunol 2022; 74: 101626.

    OpenUrl
22. 22.↵
    1. Huang Y,
    2. Wu Y,
    3. Zeng L,
    4. Shan W,
    5. Huang L.

    The tumor suppressor role of microRNA-338-3p in renal cell carcinoma. Oncol Lett 2018; 16: 2195–2200.

    OpenUrlCrossRefPubMed